08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Hereditary Neuropathy Foundation, BioPontis deal

The foundation and alliance formed a JV to develop drugs to treat Charcot-Marie-Tooth (CMT) disease, which is a hereditary motor sensory neuropathy. BioPontis will manage the JV’s scientific execution, regulatory strategy, patenting and business partnering....
07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

BioPontis Alliance LLC, UMMS deal

BioPontis and the medical school partnered to discover treatments for cancer, neurological disorders and other diseases. BioPontis will review research at the university and will provide financial support to university faculty. BioPontis focuses on translating...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

BioPontis, University of Kansas deal

The university partnered with BioPontis, which said it is focused on translating university research into clinical candidates for pharmas to treat cancer, infectious and inflammation diseases and neurological indications. BioPontis is partnered with at least...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because...
07:00 , Aug 4, 2011 |  BC Innovations  |  Finance

Gap-filling alliance

BioPontis Alliance LLC is taking a fresh approach to addressing the translational gap-instead of taking discoveries from universities and forming companies, BioPontis starts with its knowledge of industry's portfolio needs and works backward. The company...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

BioPontis, J&J deal

Johnson & Johnson's Janssen Biotech Inc. subsidiary will provide guidance on BioPontis' early science and development programs in-licensed from its university partners to help ensure that BioPontis' programs align with market demand. Janssen will also...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

BioPontis, Pfizer deal

Pfizer will provide guidance on BioPontis' product portfolio in-licensed from its university partners to help ensure that BioPontis invests in development programs that align with "clinical need and market demand." Pfizer will also evaluate and...
08:00 , Mar 10, 2011 |  BC Innovations  |  Targets & Mechanisms

De-amping the HER2 environment

A team from the University of Pennsylvania School of Medicine and another from the Massachusetts General Hospital Cancer Center and Cyclacel Pharmaceuticals Inc. have independently identified strategies to improve clinical outcomes for patients with HER2-positive...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Company News

BioPontis Alliance LLC, Merck deal

Merck and BioPontis partnered to evaluate preclinical research BioPontis has in-licensed from its university partners. Merck will have the option to evaluate and contribute to research conducted by BioPontis. The pharma will also have the...